1STONE G W, MOLITERNO D J, BERTRAND M,et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein Ⅱb/Ⅲa in hibitors inpatients undergoing coronary stenting the TARGET trial[J]. Circulation, 2002,105 ：2345- 2354.
2CROUCH M A, NAPPI J M, CHEANG K I. Glycoprotein Ⅱb/Ⅲa receptor inbibitors in percutan coronary intervention and acute coronary syndrome [J].Ann Pharmacother, 2003, 37: 860-875.
3FUSTER V, BADIMON L, BADIMON J J, et al.The pathogenesis of coronary artery disease and the acute coronary syndromes [J]. N Engl J Med, 1992,326: 242- 250.
4The Restore Investigators. Effects of platelet Glycoprotein Ⅱb/Ⅲa Blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J]. Circulation ,1997, 96: 1445-1453.
5The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲ a receptor with tirofiban in unstable angina and non-Q-wave rnyocardial infarction[J]. N Engl J Med, 1998, 338:1488-1497.
6BOERSMA E, HARRINGTON R A, MOLITERNO D J, et al. Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet, 2002, 359:189-198.
7TCHENG J E, ELLIS S G, GEORGE B S, et al.Pharmacodynamics of chimetic glycoprotein Ⅱb/Ⅲa integrin antiplatelet antibody Fab TEs in high-risk coronary angioplasty[J]. Circulation, 1994, 90:1757-1764.
5Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
8Kloner RA, Ganote CE, Jennings RB. The " no-reflow" phenomenon after temporary coronary occlusion in the dog [J]. J Clin Invest, 1974, 54 (6): 1496-1508.
9Johnson WB,Malone SA,Pantely GA, et al. No reflow and extent of infarction during maximal vasodilation in the porcine heart[J]. Circulation, 1988,78 (2) :462-472.
10Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention [J]. J Am Coll Cardiol, 2001,37 (8): 2059-2065.
